NEW YORK, Oct. 05, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PetMed Express, Inc. (NASDAQ:PETS) from May 8, 2017 through August 23, 2017, inclusive (the “Class Period”) of the important October 24, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for PetMed investors under the federal securities laws.
To join the PetMed class action, go to http://rosenlegal.com/cases-1199.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) PetMed was marketing dangerous and addictive animal drugs to humans; (2) as such, PetMed is vulnerable to potential civil or criminal liability, as well as other regulatory action; (3) in turn, Google may halt PetMed’s advertising activities; and (4) as a result, defendants’ statements about PetMed’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 24, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1199.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
OpenAI Addresses Security Vulnerability in macOS App Certification Process
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 



